UBS raised the firm’s price target on Bristol Myers (BMY) to $70 from $65 and keeps a Buy rating on the shares. The Phase III Milvexian SSP and AFib data coming in H2 is one of Bristol Myers’ major catalysts this year, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers Squibb call volume above normal and directionally bullish
- Barclays Names Eli Lilly (LLY) and Bristol-Myers Squibb (BMY) as Top Pharma Stocks to Buy Now
- Prothena expects to end year with $255M in cash, equivalents
- Tango Therapeutics weakness an ‘over reaction,’ says Stifel
- Bristol Myers: Biokin reports ‘positive’ results from Phase 3 study of iza-bren